Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3691 Efficacy of 177Lu-octreotate in biliary duct neuroendocrine tumor

Introduction: We report the case of a 69-year-old woman presenting a biliary duct neuroendocrine tumor, diagnosed in 2003 treated by extrahepatic biliary tract resection.

Conference:

Presenting Author:

Authors: Kelly A, Otman H, Petorin C, Perret-Boire S, Chanchou M,

Keywords: 177Lu-octreotate, biliary duct neuroendocrine tumor,

#3212 CLARINET FORTE: Characterization of Pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with Lanreotide Autogel (LAN) 120 mg every 14 days (q14d)

Introduction: CLARINET FORTE investigated efficacy and safety of LAN 120 mg q14d (frequent dose) in patients with pancreatic (panNET) or midgut NETs after progression while on LAN 120 mg every 28 days (q28d; standard dose) (NCT02651987).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Dehez M, Brendel K, Sarr C, Björnsson M, Truong Thanh X,

Keywords: NET, PK, PFS, tumor size, safety, somatostatin analogues, high dose,

#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,